During the EuroPCR 2017, I presented the results of the first year of Follow-Up for the RAI Registry, a spontaneous, multicenter, prospective data collection on consecutive patients undergoing BVS implantation in Italy.
The Objective of the Registry is to evaluate the long-term safety and efficacy of Absorb BVS within an unrestricted cohort of patients undergoing PCI. There have been enrolled 1505 Patients in 25 Italian Centers.
•The RAI registry represents a real world, contemporary
BVS population, with very few exclusion criteria.
• The population enrolled is extremely well treated
• Current-era BVS use, according to specific and
standardized techniques of implantation, show good
clinical outcome in an unrestricted patient population at
mid-term follow up.
Here’s the presentation of the meeting2 RAI 12m